4.6 Article

Risk factors for hepatic decompensation in patients with primary biliary cirrhosis

期刊

WORLD JOURNAL OF GASTROENTEROLOGY
卷 19, 期 7, 页码 1111-1118

出版社

BAISHIDENG PUBL GRP CO LTD
DOI: 10.3748/wjg.v19.i7.1111

关键词

Primary biliary cirrhosis; Risk factor; Hepatic decompensation; Survival; Ursodeoxycholic acid response; Anti-centromere antibodies; Histological stage

资金

  1. National Science Technology Pillar Program in the 11th Five-Year Plan [2008BAI59B03]
  2. Research Special Fund for the Public Welfare Industry of Health [201202004]

向作者/读者索取更多资源

AIM: To examine the clinical features and analyze prognostic factors in a prospective study of primary biliary cirrhosis (PBC) patients. METHODS: From 1995 to 2010, PBC patients without hepatic decompensation seen at the Peking Union Medical College Hospital were enrolled. Clinical signs and manifestations (pruritus, persistent fatigue, jaundice and pain in the right hypochondrium), laboratory parameters (auto-antibodies for autoimmune hepatic disease, biliary and hepatic enzymes, immunoglobulin, bilirubin, and albumin) and imaging findings were recorded at entry and at specific time points during follow-up. Cox regression and Kaplan-Meier analyses, respectively, assessed the risk factors for hepatic decompensation and survival. RESULTS: Two hundred and sixty-two PBC patients were enrolled with a median follow-up of 75.2 mo (range, 21-201 mo). The 240 patients were aged 51.5 +/- 10.2 years at diagnosis and 91.6% were female. Two hundred and forty-five (93.5%) were seropositive for anti-mitochondrial antibodies. At presentation, 170 patients (64.9%) were symptomatic, while 96 patients (36.6%) had extra-hepatic autoimmune disease. During the follow-up period, 62 (23.7%) patients developed hepatic decompensation of whom four underwent liver transplantation and 17 died. The cumulative survival rate and median survival time were 83.9% and 181.7 mo, respectively. Cox regression analysis revealed that an incomplete ursodeoxycholic acid (UDCA) response or inconsistent treatment [P < 0.001; hazard risk (HR) 95% CI = 2.423-7.541], anti-centromere antibodies (ACA) positivity (P < 0.001; HR 95% CI = 2.516-7.137), alanine aminotransferase ratio (AAR) elevations (P < 0.001; HR 95% CI = 1.357-2.678), and histological advanced liver disease (P = 0.006; HR 95% CI = 1.481-10.847) were predictors of hepatic decompensation. The clinical features and survival of PBC in China are consistent with those described in Western countries. CONCLUSION: Incomplete UDCA response or inconsistent treatment, ACA positivity, AAR elevations, and advanced histological stage are predictors of decompensation. (C) 2013 Baishideng. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据